Turn Biotechnologies (Turn Bio) has entered an exclusive worldwide licensing agreement with HanAll Biopharma to develop therapies for age-related eye and ear ailments.

The value of the deal's initial product is expected to exceed $300m.

The partnership will leverage Turn Bio's Epigenetic Reprogramming of Age technology and its eTurna delivery platform.

These offerings are designed to reinstate ideal gene expression by fighting aging at a cellular level - thereby treating and curing chronic ailments.

Turn Biotechnologies CEO Anja Krammer stated: “This partnership is a milestone for Turn Bio. With HanAll's support, we are accelerating the development of transformative therapies for eye and ear indications, which can benefit patients around the world.”

HanAll's initial investment in Turn Bio in 2022 laid the groundwork for this expanded collaboration.

The company has since been closely monitoring Turn Bio's advancements, particularly the potential of its epigenetic reprogramming technology.

With this agreement, Turn Bio will extend its research focus beyond dermatology and immunology, addressing conditions affecting the eyes and ears, both commonly impacted by aging.

HanAll Biopharma CEO Sean Jeong stated: “Turn Bio's innovative approach to epigenetic reprogramming aligns closely with HanAll's mission to explore innovative medicines to expand our therapeutic area.

“Together, we are poised to pioneer new treatments that address critical unmet needs, particularly in aging-related diseases.”

In May 2023, HanAll and Daewoong Pharmaceutical entered a co-development deal with NurrOn Pharmaceuticals to develop treatments for Parkinson’s disease and other neurodegenerative disorders.